Oric Pharmaceuticals
Clinical trials sponsored by Oric Pharmaceuticals, explained in plain language.
-
Can a Two-Drug attack stall resistant prostate cancer?
Disease control Recruiting nowThis phase 3 trial is testing whether adding an experimental drug called rinzimetostat to the standard drug darolutamide can slow the progression of metastatic castration-resistant prostate cancer better than current treatments. The study enrolls men whose cancer has worsened aft…
Phase: PHASE3 • Sponsor: ORIC Pharmaceuticals • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug ORIC-944 targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis trial investigates a new oral drug called ORIC-944, given alone or combined with standard hormone therapies, for men with metastatic prostate cancer that has spread beyond the prostate. The study aims to find the safest dose and check for early signs that the drug can contro…
Phase: PHASE1 • Sponsor: ORIC Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug combo targets tough lung cancer mutation
Disease control Recruiting nowThis early-stage trial tests a new oral drug called ORIC-114 combined with an injectable drug, amivantamab, in people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The study aims to find the safest dose and see if the combination shrinks tu…
Phase: PHASE1 • Sponsor: ORIC Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC